The Manila Times

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary S…

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...
Fierce Pharma

Biovac nets $108M finance package to build Africa’s first fully integrated vaccine plant

Biovac has secured a $108.3 million financing package that will allow the South African pharma company to build the continent ...
The Manila Times

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug S…

Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the ...

Biogen Inc.: Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab - a CD38-directed a ...

Inside NASA's audacious plan to build a nuclear-powered moon base

The end of the historic Artemis II mission kicks off a race to establish a permanent human presence on the moon.

FDA seeks more power over drug ads, advisory panels

The Trump administration dropped its fiscal 2027 budget request Friday, and the massive document release includes some notable legislative proposals for the FDA.

TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, ...

AIM ImmunoTech Inc.: AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer, Backed by Positive Clinical Signals ...

Company to participate in Live Virtual Investor Closing Bell segment today, April 16th?at?4:00 PM ET- Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (N ...
Euronext Markets Live

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria. Approval in CSU for children two to ...

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic ...

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...